[Clinical evaluation of procaterol and salbutamol in patients with bronchial asthma].
When the beta-2-selectivity of beta-agonists is assessed in man it is always considerably less than would be expected from studies on isolated tissues. That was a reason why this study was taken. As we know procaterol has been included into group of beta-2-selective non-catecholamines with a reasonably long duration of action. We performed clinical evaluation of procaterol and salbutamol on 24 patients with bronchial asthma. Procaterol was administered per os (tabl. a 50 micrograms twice daily) during 4 weeks, and next salbutamol was replaced above mentioned (tabl. a 8 mg twice daily) also during 4 weeks. Clinical symptoms and spirometric values were analyzed. Obtained results indicated that procaterol and salbutamol showed a similar potency in spirometric examination in patients with bronchial asthma. Observed side effects after procaterol were less often than after salbutamol.
Płusa
T
T
II Kliniki Chorób Wewnetrznych Instytutu Medycyny Wewnetrznej Centralnego Szpitala Klinicznego WAM, Warszawie.
Zaraś
E
E
Kruszewski
J
J
D000293:Adolescent; D000328:Adult; D000420:Albuterol / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017265:Procaterol / Q000009:adverse effects / Q000627:therapeutic use*
D000420:Albuterol; D017265:Procaterol
Kliniczna ocena prokaterolu i salbutamolu u chorych na astme oskrzelowa.